- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT07782112
Best Salvage Treatment for High-risk Relapsing Prostate Cancer (PEACE-9 - ESCALATE-RT) (ESCALATE-RT)
PEACE-9 - ESCALATE-RT: A Phase III Randomized Study in Patients With High-risk PSA Relapse After Local Therapy Treated With Enzalutamide Plus Androgen Deprivation Therapy and Comparing MDT ± Pelvic Radiotherapy Versus no Further Treatment
The goal of this clinical trial is to learn if adding metastasis-directed radiotherapy with or without pelvic salvage radiotherapy, to intermittent prostate cancer drugs (intensified hormone therapy) can delay the need to restart these drugs in men with oligometastactic prostate cancer recurrence.
In practice, this study is open to men whose PSA level (a blood marker of cancer activity) is rising as defined by biochemical recurrence, and who have 1 to 5 areas of cancer spread (1 to 5 metastases defining oligometastatic status) found on a specialized scan (PSMA PET/CT).
Since intensified hormone therapy, including androgen deprivation therapy combined with a next-generation hormone therapy, represents the standard treatment strategy for these patients, researchers want to find out if adding radiation therapy can help patients to spend more time off cancer drugs while keeping their cancer under control.
The main questions this trial aims to answer are:
- Does adding radiation therapy to each metastases with or without pelvic area, lengthen the time before participants need to restart drug treatment?
- Does adding radiation therapy increase the number of participants whose PSA drops to a very low level (0.2 ng/mL or lower)?
- Does adding radiation therapy affect participants' quality of life?
Researchers will randomly assign participants (chosen by chance) to receive either enzalutamide (next-generation hormone therapy) plus androgen-deprivation therapy (first-generation hormone therapy ) alone, or the same association of these drugs combined with radiation therapy aimed at each metastases with or without pelvic area.
This comparison will show whether adding radiation therapy helps participants reach a deeper PSA response and go longer without needing cancer drugs.
Participants will:
- Take enzalutamide and androgen-deprivation therapy for 9 months
- Have an equal chance of also receiving radiation therapy to each metastases with or without pelvic area
- Stop drug treatment after 9 months if their PSA drops below 0.2 ng/mL, a level showing the cancer is well controlled
- Restart drug treatment if their PSA rises again during the treatment-free period
- Have regular blood tests and clinic visits to check their PSA, testosterone, and overall health
- Complete short quality-of-life questionnaires during the study
- Take part in a study conducted at several hospitals in Switzerland, Belgium, and France.
Visão geral do estudo
Status
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 3
Contactos e Locais
Contato de estudo
- Nome: Thomas Zilli, MD
- Número de telefone: + 41 918118675
- E-mail: thomas.zilli@eoc.ch
Estude backup de contato
- Nome: Tatiana Terrot
- E-mail: Tatiana.Terrot@eoc.ch
Locais de estudo
-
-
-
Aalst, Bélgica
- AZorg Aalst
-
Contato:
- Mark De Ridder, MD
-
Antwerp, Bélgica
- Iridium Netwerk
-
Contato:
- Piet Ost, MD, PhD
-
Bruges, Bélgica
- AZ Sint-Jan
-
Contato:
- Sarah Roels, MD
-
Brussels, Bélgica
- Institut Bordet - HUB Brussel
-
Contato:
- Dirk Van Gestel, MD
-
Hasselt, Bélgica
- Jessa Ziekenhuis
-
Contato:
- Philippe Bulens, MD
-
Kortrijk, Bélgica
- AZ Groeninge
-
Contato:
- Aurélie De Bruycker, MD
-
Mechelen, Bélgica
- AZ Sint-Maarten Mechelen
-
Contato:
- Cédric Draulans, MD
-
-
-
-
-
Bordeaux, França
- Institut Bergonie
-
Contato:
- Vérane Achard, MD, PhD
-
Lille, França
- Centre Oscar Lambret
-
Contato:
- David Pasquier, MD, PhD
-
Saint-Etienne, França
- CHU de Saint-Etienne
-
Contato:
- Nicolas Vial, MD
- E-mail: nicolas.vial@chu-st-etienne.fr
-
Contato:
- E-mail: nicolas.vial@chu-st-etienne.fr
-
Saint-Herblain, França
- Institut de Cancérologie de l'Ouest
-
Contato:
- Stéphane Supiot, MD, PhD
-
Villejuif, França
- Institut Gustave Roussy
-
Contato:
- Pierre Blanchard, MD, PhD
-
-
-
-
-
Aarau, Suíça
- KSA
-
Contato:
- Stephanie Thoma, MD
- E-mail: stephanie.thoma@ksa.ch
-
Bellinzona, Suíça, 6500
- IOSI-EOC
-
Contato:
- Thomas Zilli, MD
- Número de telefone: + 41 918118675
- E-mail: thomas.zilli@eoc.ch
-
Bern, Suíça
- Inselspital
-
Contato:
- Mohamed Shelan, MD
- E-mail: Mohamed.Shelan@insel.ch
-
Chur, Suíça
- KSGR
-
Contato:
- Efstratios Karagiannis, MD, PhD
- E-mail: Efstratios.Karagiannis@ksgr.ch
-
Münsterlingen, Suíça
- Spital Thurgau
-
Contato:
- Michael Mayinger, MD
- E-mail: michael.mayinger@team-radiologie.ch
-
Winterthur, Suíça
- KSW
-
Contato:
- Daniel Zwahlen, MD
- E-mail: daniel.zwahlen@ksw.ch
-
Zurich, Suíça
- USZ
-
Contato:
- Matthias Guckenberger, MD
- E-mail: Matthias.Guckenberger@usz.ch
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
- Adulto
- Adulto mais velho
Aceita Voluntários Saudáveis
Descrição
Inclusion Criteria:
- Histologically proven initial diagnosis of adenocarcinoma of the prostate
- Rising PSA after local therapy as defined by PSA ≥ 0.2 ng/mL after RP +/- adjuvant/salvage prostate bed RT and at least 2 ng/mL above nadir for primary RT, with a PSADT ≤ 9 months
- Serum Testosterone ≥ 150 ng/dl (6.9343 nM/L)
- On PSMA PET/CT restaging presence of: 1 to 5 distant metastases that are amenable to MDT ± N1 patients (no limit in the number of nodes)
- ECOG performance status 0 - 2
- Age > or =18 years
- Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule; those conditions should be discussed with the patient before registration in the trial
- Before patient registration/randomization, written informed consent must be given according to ICH/GCP, and national/local regulations
Exclusion Criteria:
- More than 5 distant PSMA positive metastases and/or brain or leptomeningeal metastases.
- Prostate recurrence (positive PSMA disease) after primary prostate irradiation
- Prostate bed recurrence (positive PSMA disease) after salvage/adjuvant irradiation
- Pelvic nodal recurrence (positive PSMA disease) after primary WPRT irradiation
- Contraindications to pelvic RT and/or MDT
- Prior evidence of distant metastatic disease
- Contraindications to ADT
- Contraindication for treatment with enzalutamide
- Prior hormonal therapy (Neoadjuvant/adjuvant therapy to treat PCa ≤ 36 months in duration and ≥ 9 months before randomization is allowed)
- Previous treatment with cytotoxic agent for PCa
- Any active malignancies (i.e., progressing or requiring any treatment in the previous 36 months) other than prostate cancer (except non-muscle invasive bladder cancer; non-melanomatous skin cancer or a malignancy that is considered cured with minimal risk of recurrence
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Comparador Ativo: ADT plus Enzalutamide
Enzalutamide 160 mg daily + androgen deprivation therapy for 9 months, suspended if PSA < 0.2 ng/mL, followed by PSA monitoring until progression
|
|
|
Experimental: ADT plus Enzalutamide plus Radiotherapy (MDT +/- WPRT)
Enzalutamide 160 mg daily + androgen deprivation therapy for 9 months, suspended if PSA < 0.2 ng/mL, followed by PSA monitoring until progression + Radiotherapy for MDT ± WPRT
|
Participants receive metastasis-directed therapy (MDT) alone or combined with prostate-bed radiotherapy (PB-RT) and/or whole pelvic radiotherapy (WPRT), as follows (radiotherapy is tailored to each participant's prior curative treatment for prostate cancer, to avoid re-irradiating previously treated volumes) :
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to first re-initiation of treatment
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
• Time to first re-initiation of treatment calculated from randomization to the occurrence of one of the following events:
Death in the absence of progressive disease will be considered as a competing risk for this endpoint. |
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Time to PSA progression
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Time to PSA progression: defined by the time from the day of PSA nadir and the day when the PSA increase of ≥ 25% and an absolute increase of ≥ 2 ng/mL above the nadir.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
PFS (Progression-Free Survival)
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
PFS: defined as the time from randomization to the first progression or death (progression being defined by the appearance of a new recurrence (any N1 or M1) as suggested by PET-CT, or symptoms related to progressive prostate cancer, or death due to any cause).
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
MFS (Metastasis-Free Survival)
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
MFS: defined as time between randomization and the appearance of a new metastatic recurrence (any M1) as suggested by PET-CT, or death due to any cause.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
OS (Overall Survival)
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
OS: defined as the time from randomization to death to any cause.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
PSA response
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
PSA response: defined by a PSA < 0.2 ng/ml at 9 months.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Pattern of progression
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Local/regional/distant recurrence will be analyzed:
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Time to castration-resistant disease
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Time to castration-resistant disease is defined as the time from trial randomization until castration-resistant status, defined as a castrate serum testosterone level below 50 ng/dL (1.7 nmol/L) plus either biochemical progression or radiological progression.
Biochemical progression is defined as three consecutive rises in PSA at least 1 week apart, resulting in two 50% increases over the nadir, with a PSA level above 2 ng/mL.
Radiological progression is defined as the appearance of two or more new bone lesions on bone scan, or enlargement of a soft tissue lesion using RECIST (Response Evaluation Criteria in Solid Tumours).
Symptomatic progression alone is not sufficient to diagnose castration-resistant prostate cancer (CRPC).
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Adverse events
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Adverse events: acute (during the first 3 months after the end of MDT ± WPRT and late (3 months after the end of MDT ± WPRT).
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Quality of life (QoL) - EORTC QLQ-C30
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
EORTC Quality of Life Questionnaire Core 30 (QLQ-C30), version 3, a 30-item questionnaire.
Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much"), except the two global health status/QoL items, rated on a 7-point scale (1 = "Very poor" to 7 = "Excellent").
Raw scores are linearly transformed to a 0-100 scale.
Higher scores indicate better functioning/quality of life on the functional and global health scales, and greater symptom burden on the symptom scales.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Quality of Life - EORTC QLQ-PR25
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
EORTC Quality of Life Questionnaire Prostate Cancer Module (QLQ-PR25), a 25-item module supplementing the QLQ-C30.
Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much").
Raw scores are linearly transformed to a 0-100 scale.
Higher scores indicate greater symptom burden, except for sexual activity/functioning scales, where higher scores indicate better functioning.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
|
Quality of Life - EORTC IL-249
Prazo: From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
A customised 22-item list from the EORTC IL-249, assessing general symptoms, weight-related issues, and sexual quality of life.
Items are rated on a 4-point scale (1 = "Not at all" to 4 = "Very much").
Raw scores are linearly transformed to a 0-100 scale; higher scores indicate a greater burden of symptoms or issues.
|
From the start of Androgen Deprivation Therapy plus Enzalutamide to 5 years after this date
|
Colaboradores e Investigadores
Patrocinador
Colaboradores
Investigadores
- Investigador principal: Thomas Zilli, MD, IOSI-EOC
- Cadeira de estudo: Bertrand Tombal, MD, PhD, Urology, Cliniques Universitaires Saint Luc, Bruxelles, Belgium
- Cadeira de estudo: Piet Ost, MD, PhD, Department of Human Structure and Repair, Ghent University, Ghent, Belgium; Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium
- Cadeira de estudo: Silke Gillessen, MD, IOSI-EOC
- Cadeira de estudo: Piet Dirix, MD, PhD, Department of Radiation Oncology, Iridium Network, Wilrijk, Belgium
- Cadeira de estudo: Salvatore Cozzi, MD, IOSI-EOC
- Cadeira de estudo: Nicolas Vial, MD, University Hospital of Saint-Etienne
Publicações e links úteis
Publicações Gerais
- Crook JM, O'Callaghan CJ, Duncan G, Dearnaley DP, Higano CS, Horwitz EM, Frymire E, Malone S, Chin J, Nabid A, Warde P, Corbett T, Angyalfi S, Goldenberg SL, Gospodarowicz MK, Saad F, Logue JP, Hall E, Schellhammer PF, Ding K, Klotz L. Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med. 2012 Sep 6;367(10):895-903. doi: 10.1056/NEJMoa1201546.
- Nguyen PL, Kollmeier MA, Rathkopf DE, Hoffman KE, Zurita AJ, Spratt DE, Dess RT, Liauw SL, Szmulewitz RZ, Einstein DJ, Bubley GJ, Yu JB, An Y, Wong AC, Feng FY, McKay RR, Rose BS, Shin KY, Kibel AS, Taplin ME. FORMULA-509: A Multicenter Randomized Trial of Postprostatectomy Salvage Radiotherapy and 6 months of a GNRH Agonist with Either Bicalutamide or Abiraterone Acetate plus Prednisone and Apalutamide. Eur Urol. 2026 Feb 10:S0302-2838(25)04854-7. doi: 10.1016/j.eururo.2025.12.001. Online ahead of print.
- Tang C, Sherry AD, Hwang H, Farris DP, Francolini G, Di Cataldo V, Livi L, Tran P, Corn PG, Aparicio A, Simontacchi G, Kiess AP, Wang JH, Fonteyne V, Bultijnck R, Phillips R, Deek MP, Olson R, Harrow S, Marvaso G, Lorubbio C, Jereczek-Fossa BA, Ludmir EB, Blanchard P, Warner A, Sun R, Palma DA, Ost P. Metastasis-directed therapy and standard of care versus standard of care for oligometastatic prostate cancer (WOLVERINE): a systematic review and individual patient data meta-analysis from the X-MET collaboration. Lancet Oncol. 2026 Feb;27(2):181-190. doi: 10.1016/S1470-2045(25)00658-8.
- Tang C, Sherry AD, Haymaker C, Bathala T, Liu S, Fellman B, Cohen L, Aparicio A, Zurita AJ, Reuben A, Marmonti E, Chun SG, Reddy JP, Ghia A, McGuire S, Efstathiou E, Wang J, Wang J, Pilie P, Kovitz C, Du W, Simiele SJ, Kumar R, Borghero Y, Shi Z, Chapin B, Gomez D, Wistuba I, Corn PG. Addition of Metastasis-Directed Therapy to Intermittent Hormone Therapy for Oligometastatic Prostate Cancer: The EXTEND Phase 2 Randomized Clinical Trial. JAMA Oncol. 2023 Jun 1;9(6):825-834. doi: 10.1001/jamaoncol.2023.0161.
- Holzgreve A, Armstrong WR, Clark KJ, Benz MR, Smith CP, Djaileb L, Gafita A, Thin P, Nickols NG, Kishan AU, Rettig MB, Reiter RE, Czernin J, Calais J. PSMA-PET/CT Findings in Patients With High-Risk Biochemically Recurrent Prostate Cancer With No Metastatic Disease by Conventional Imaging. JAMA Netw Open. 2025 Jan 2;8(1):e2452971. doi: 10.1001/jamanetworkopen.2024.52971.
- Bukavina L, Luckenbaugh AN, Hofman MS, Hope T, Kamran SC, Murphy DG, Yamoah K, Ost P. Incorporating Prostate-specific Membrane Antigen Positron Emission Tomography in Management Decisions for Men with Newly Diagnosed or Biochemically Recurrent Prostate Cancer. Eur Urol. 2023 Jun;83(6):521-533. doi: 10.1016/j.eururo.2022.10.024. Epub 2022 Nov 18.
- Shore ND, Luz MA, De Giorgi U, Gleave M, Gotto GT, Pieczonka CM, Haas GP, Kim CS, Ramirez-Backhaus M, Rannikko A, Kalac M, Sridharan S, Rosales M, Tang Y, Tutrone RF Jr, Venugopal B, Villers A, Woo HH, Wang F, Freedland SJ. Improved Survival with Enzalutamide in Biochemically Recurrent Prostate Cancer. N Engl J Med. 2026 Feb 5;394(6):563-575. doi: 10.1056/NEJMoa2510310. Epub 2025 Oct 19.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Estimado)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças urogenitais
- Doenças Genitais
- Neoplasias Genitais Masculinas
- Neoplasias urogenitais
- Neoplasias por local
- Neoplasias
- Doenças Genitais, Masculino
- Doenças prostáticas
- Doenças Urogenitais Masculinas
- Neoplasias prostáticas
- Efeitos fisiológicos das drogas
- Hormônios, substitutos hormonais e antagonistas hormonais
- Antagonistas hormonais
- Terapêutica
- Ações farmacológicas
- Ações e usos químicos
- Antagonistas andrógenos
- Radioterapia
- enzalutamida
Outros números de identificação do estudo
- PEACE-9 - ESCALATE-RT
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
produto fabricado e exportado dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .